Swiss Consensus Statement: Recommendations for optimising re-treatment with MabThera® (rituximab) in rheumatoid arthritis. Swiss Medical Weekly, [S. l.], v. 140, n. 2728, p. w13073, 2010. DOI: 10.4414/smw.2010.13073. Disponível em: https://www.smw.ch/index.php/smw/article/view/1150. Acesso em: 11 jan. 2026.